Sanara MedTech Sales Jump 28 Percent
Sanara MedTech (NASDAQ:SMTI), a developer of surgical wound care products and value-based care technology, reported its Q2 FY2025 earnings on August 13, 2025. The report showed the company’s GAAP net revenue beat expectations, growing to $25.83 million compared to an analyst estimate of $25.15 million. Earnings per share (EPS) loss of $(0.23) (GAAP) also surpassed the consensus estimate for a larger loss of $(0.44). The company recorded a GAAP net loss of $2.0 million, narrower than the $3.53 million net loss in Q2 2024. Adjusted EBITDA (non-GAAP) more than quadrupled from a year earlier, reaching $2.66 million (non-GAAP). The quarter reflected margin gains and growth in the core surgical business, even as net loss increased in the value-based care segment (Tissue Health Plus) during the first half of 2025. Management’s overall assessment emphasized strong execution in the surgical business, with the Tissue Health Plus segment now under a formal strategic review.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Sanara MedTech specializes in medical technologies for improving surgical wound care and recovery. Its product suite covers soft tissue repair, bone fusion, and a digital wound care platform for providers. At its core, the business develops and sells products such as CellerateRX Surgical (a wound care collagen technology) and BIASURGE (an advanced irrigation solution) into hospitals and surgical centers.
Source Fool.com
